loadpatents
Patent applications and USPTO patent grants for OBIKA; Satoshi.The latest application filed is for "molecular targeted nucleic acid medicine for gastric cancer".
Patent | Date |
---|---|
Molecular Targeted Nucleic Acid Medicine For Gastric Cancer App 20220282248 - KANDA; Mitsuro ;   et al. | 2022-09-08 |
Production Of Bridged Artificial Nucleosides App 20220177509 - BABA; Takeshi ;   et al. | 2022-06-09 |
Nucleic Acid Compound And Oligonucleotide App 20220169671 - OBIKA; Satoshi ;   et al. | 2022-06-02 |
Antisense Oligonucleic Acid App 20220170020 - OBIKA; Satoshi ;   et al. | 2022-06-02 |
Antisense Nucleic Acid Targeting Pcsk9 App 20220160880 - Harada-Shiba; Mariko ;   et al. | 2022-05-26 |
5'-modified Nucleoside And Nucleotide Using Same App 20220127300 - OBIKA; Satoshi ;   et al. | 2022-04-28 |
Nucleic acid compound and oligonucleotide Grant 11,286,275 - Obika , et al. March 29, 2 | 2022-03-29 |
Antisense nucleic acid targeting PCSK9 Grant 11,273,222 - Harada-Shiba , et al. March 15, 2 | 2022-03-15 |
Antisense oligonucleic acid Grant 11,261,440 - Obika , et al. March 1, 2 | 2022-03-01 |
.alpha.-synuclein expression inhibitor Grant 11,234,995 - Nakamori , et al. February 1, 2 | 2022-02-01 |
Crosslinked Artificial Nucleic Acid Alna App 20220002336 - SAWAMOTO; Hiroaki ;   et al. | 2022-01-06 |
Chimeric Double-stranded Nucleic Acid App 20210340540 - Yokota; Takanori ;   et al. | 2021-11-04 |
Antisense Oligonucleotide Targeting Arl4c Molecule, And Nucleic Acid Drug Using Antisense Oligonucleotide App 20210317459 - KIKUCHI; Akira ;   et al. | 2021-10-14 |
Small Cell Lung Cancer Therapeutic Agent Containing Oligonucleotide App 20210277398 - SHIMOJO; Masahito ;   et al. | 2021-09-09 |
Chimeric double-stranded nucleic acid Grant 11,034,955 - Yokota , et al. June 15, 2 | 2021-06-15 |
Antisense Nucleic Acid Targeting Pcsk9 App 20210170032 - Harada-Shiba; Mariko ;   et al. | 2021-06-10 |
Antisense Nucleic Acid For Inhibiting Biosynthesis Of Chondroitin App 20210102214 - OBIKA; Satoshi ;   et al. | 2021-04-08 |
Bridged nucleic acid GuNA, method for producing same, and intermediate compound Grant 10,961,269 - Obika , et al. March 30, 2 | 2021-03-30 |
ENA ANTISENSE OLIGONUCLEOTIDE FOR INHIBITION OF alpha-SYNUCLEIN EXPRESSION App 20200172903 - NAKAMORI; Masayuki ;   et al. | 2020-06-04 |
Nucleic Acid Compound And Oligonucleotide App 20200055890 - OBIKA; Satoshi ;   et al. | 2020-02-20 |
Antisense Oligonucleic Acid App 20200056178 - OBIKA; Satoshi ;   et al. | 2020-02-20 |
Chimeric Double-stranded Nucleic Acid App 20190270996 - YOKOTA; TAKANORI ;   et al. | 2019-09-05 |
Oligonucleotide and artificial nucleoside having guanidine bridge Grant 10,377,789 - Obika , et al. A | 2019-08-13 |
Chimeric double-stranded nucleic acid Grant 10,337,006 - Yokota , et al. | 2019-07-02 |
Chimeric double-stranded nucleic acid Grant 10,329,567 - Yokota , et al. | 2019-06-25 |
Double-stranded antisense nucleic acid with exon-skipping effect Grant 10,190,117 - Yokota , et al. Ja | 2019-01-29 |
a-SYNUCLEIN EXPRESSION INHIBITOR App 20190008886 - NAKAMORI; Masayuki ;   et al. | 2019-01-10 |
Chimeric Double-stranded Nucleic Acid App 20180320181 - Yokota; Takanori ;   et al. | 2018-11-08 |
Crosslinked Nucleic Acid Guna, Method For Producing Same, And Intermediate Compound App 20180251488 - OBIKA; Satoshi ;   et al. | 2018-09-06 |
Chimeric Double-stranded Nucleic Acid App 20180073024 - YOKOTA; TAKANORI ;   et al. | 2018-03-15 |
Chimeric double-stranded nucleic acid Grant 9,816,089 - Yokota , et al. November 14, 2 | 2017-11-14 |
Antisense Antineoplastic Agent App 20170211073 - Nakano; Kenji ;   et al. | 2017-07-27 |
Crosslinked nucleoside and nucleotide Grant 9,611,479 - Obika , et al. April 4, 2 | 2017-04-04 |
Crosslinked Nucleoside And Nucleotide App 20170044528 - OBIKA; Satoshi ;   et al. | 2017-02-16 |
Double-stranded Antisense Nucleic Acid With Exon-skipping Effect App 20160130583 - YOKOTA; Takanori ;   et al. | 2016-05-12 |
Nucleoside And Nucleotide Having Sulfonamide Structure App 20150337002 - OBIKA; Satoshi ;   et al. | 2015-11-26 |
Oligonucleotide And Artificial Nucleoside Having Guanidine Bridge App 20150266917 - Obika; Satoshi ;   et al. | 2015-09-24 |
Oligonucleotide, and therapeutic agent for dyslipidemia containing oligonucleotide as active ingredient Grant 9,127,280 - Obika , et al. September 8, 2 | 2015-09-08 |
Oligonucleotide And Therapeutic Agent For Hyperlipidemia Containing Same As Active Ingredient App 20140323709 - Obika; Satoshi ;   et al. | 2014-10-30 |
Chimeric Double-stranded Nucleic Acid App 20140302603 - Yokota; Takanori ;   et al. | 2014-10-09 |
.sup.18F-labeled azide compound, reagent for .sup.18F-labeling and method for .sup.18F-labeling of alkyne compound using same Grant 8,680,260 - Watanabe , et al. March 25, 2 | 2014-03-25 |
Bicyclonucleoside and oligonucleotide analogues Grant RE44,779 - Imanishi , et al. February 25, 2 | 2014-02-25 |
Bridged artificial nucleoside and nucleotide Grant 8,541,562 - Obika , et al. September 24, 2 | 2013-09-24 |
Oligonucleotide, And Therapeutic Agent For Dyslipidemia Containing Oligonucleotide As Active Ingredient App 20130172402 - Obika; Satoshi ;   et al. | 2013-07-04 |
Bridged Artificial Nucleoside And Nucleotide App 20120208991 - Obika; Satoshi ;   et al. | 2012-08-16 |
18f-labeled Azide Compound, Reagent For 18f-labeling And Method For 18f-labeling Of Alkyne Compound Using Same App 20120101266 - Watanabe; Yasuyoshi ;   et al. | 2012-04-26 |
Bicyclonucleoside analogues Grant 7,994,145 - Imanishi , et al. August 9, 2 | 2011-08-09 |
Nucleoside analogues and oligonucleotide derivative comprising nucleotide analogue thereof Grant 7,615,619 - Imanishi , et al. November 10, 2 | 2009-11-10 |
Artificial nucleic acids of n-o bond crosslinkage type Grant 7,427,672 - Imanishi , et al. September 23, 2 | 2008-09-23 |
Novel bicyclonucleoside analogues App 20070270370 - Imanishi; Takeshi ;   et al. | 2007-11-22 |
Novel artificial nucleic acids of n-o bond crosslinkage type App 20070167387 - Imanishi; Takeshi ;   et al. | 2007-07-19 |
Bicyclonucleoside analogues Grant 7,217,805 - Imanishi , et al. May 15, 2 | 2007-05-15 |
Nucloeside analogues and oligonucleotide derivative comprising nucleotide analogue thereof App 20060166908 - Imanishi; Takeshi ;   et al. | 2006-07-27 |
Nucleoside analogs and oligonucleotide derivatives containing these analogs Grant 7,053,199 - Imanishi , et al. May 30, 2 | 2006-05-30 |
Nucleoside analogues whose sugar moieties are bound in s-form and oligonucleotide derivatives comprising nucleotide analogues thereof App 20050176941 - Imanishi, Takeshi ;   et al. | 2005-08-11 |
Novel anitsense oligonucleotide derivatives against to hepatitis c virus App 20050059617 - Imanishi, Takeshi ;   et al. | 2005-03-17 |
Novel nucleoside analogs and oligonucleotide derivatives containing these analogs App 20040192918 - Imanishi, Takeshi ;   et al. | 2004-09-30 |
Bicyclonucleoside and oligonucleotide analogue Grant 6,770,748 - Imanishi , et al. August 3, 2 | 2004-08-03 |
Novel bicyclonucleoside analogues App 20040143114 - Imanishi, Takeshi ;   et al. | 2004-07-22 |
Novel bicyclonucleoside and oligonucleotide analogue App 20030105309 - Imanishi, Takeshi ;   et al. | 2003-06-05 |
Bicyclonucleoside and oligonucleotide analogues Grant 6,268,490 - Imanishi , et al. July 31, 2 | 2001-07-31 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.